Evidence map›Paper›PMID 40255857›Full record

ArticleFrontiers in neuroscience2025

Purinergic receptor antagonism reduces interictal discharges and rescues cognitive function in a mouse model of temporal lobe epilepsy.

Nelson Espinosa, Soraya Martín-Suárez, Ariel Lara-Vasquez, Trinidad Montero, Teresa Muro-García, German Fernandez, Juan Manuel Encinas-Pérez, Pablo Fuentealba

Abstract read
In one paragraph

Article in Frontiers in neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nelson EspinosaDepartamento de Psiquiatria, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
Soraya Martín-SuárezAchucarro Basque Center for Neuroscience, Leioa, Bizkaia, Spain.
Ariel Lara-VasquezDepartamento de Psiquiatria, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
Trinidad MonteroDepartamento de Psiquiatria, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
Teresa Muro-GarcíaAchucarro Basque Center for Neuroscience, Leioa, Bizkaia, Spain.
German FernandezDepartamento de Psiquiatria, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
Juan Manuel Encinas-PérezAchucarro Basque Center for Neuroscience, Leioa, Bizkaia, Spain.
Pablo FuentealbaDepartamento de Psiquiatria, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epilepsy is one of the most prevalent neurological disorders globally. Current treatments mainly target neuronal activity, often overlooking the involvement of astrocytes and microglia in epilepsy's pathophysiology. Here, we explored the impact of purinergic receptors, predominantly found in glial tissue, on epileptiform activity. We used TNP-ATP, a potent purinergic receptor antagonist, and conducted experiments using a mouse model of mesial temporal lobe epilepsy to examine behavioral performance and neural activity patterns. Our findings reveal that although TNP-ATP treatment did not significantly impact motor function or anxiety levels, it reduced both the amplitude and rate of hippocampal interictal discharges. Such reduction also affected the synchrony of associated neuronal spiking. Additionally, cognitive function, particularly hippocampus-dependent spatial memory and prefrontal cortex-dependent executive control, were partially restored. Moreover, neuronal recordings showed increased phase coherence between the hippocampus and prefrontal cortex for both slow (theta) and fast (gamma) oscillations in treated animals, indicating strengthened neural coordination between cortical regions upon purinergic receptor antagonism. These results underscore the potential role of purinergic receptor antagonists in improving behavioral and cognitive performance in epilepsy, providing novel insight into the use of these pharmacological agents as a therapeutic approach.

Indexed as

cognitive dysfunctioncortical oscillationinterictal dischargespurinergic receptortemporal lobe epilepsy

Identifiers

PMID40255857
PMCPMC12007451

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.